Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Innate Pharma SA
< Previous
1
2
3
Next >
Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024
July 25, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024
June 18, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
June 17, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
June 04, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
May 28, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
May 24, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Outcome of Innate Pharma’s 2024 Annual General Meeting
May 23, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma: Clarification Regarding SAR443579 Designation
May 21, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
May 15, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
May 14, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
May 07, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
April 15, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
April 15, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
April 10, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Announces Its Participation in Upcoming Investor Conference
April 09, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
April 05, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
March 21, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Announces Its Participation to Upcoming Investor Conference
March 19, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
March 14, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
March 06, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
March 06, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Announces Its Participation to Upcoming Investor Conference
February 21, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
January 04, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
January 04, 2024
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
December 19, 2023
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Announces Leadership Change
December 18, 2023
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
December 11, 2023
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
December 10, 2023
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma to Host Virtual KOL Event on Lacutamab
November 27, 2023
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update
November 14, 2023
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.